Opinion

Video

The Evolution of ALK+ NSCLC Care

Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.

Panel Introduction

This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following experts:

  • Ryan Haumschild, PharmD, MS, MBA, CPEL (Moderator) - vice president of Ambulatory Pharmacy at Emory Healthcare and Winship Cancer Institute of Emory University
  • Elizabeth Castronovo, NP - advanced practice provider
  • Martin Dietrich, MD, PhD - oncology specialist
  • Mary Grizzard, MSN, FNP - family nurse practitioner
  • Christine M. Lovly, MD, PhD, FASCO - oncology researcher/physician

Introduction and Treatment Landscape Evolution

  • Dr Haumschild introduced the program focus on ALK+ NSCLC care optimization
  • Dr Lovly posed a question regarding how the treatment landscape has evolved in recent years
  • Panelists established the foundation for discussing advances in ALK-targeted therapies

Program Overview

The panelists explore strategies for optimizing care of patients with ALK-positive non–small cell lung cancer through evidence-based treatment selection, sequencing approaches, and interpretation of emerging clinical data to improve long-term outcomes.

Related Videos
4 experts are featured in this series.
5 experts in this video
1 expert in this video
4 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
Dr Mingyang Song
Dr Samantha Garcia
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo